Accessibility Menu
Nexalin Technology logo

Nexalin Technology(NASDAQ) NXL

Current Price$0.48
Market Cap$10.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-79%
5 YearN/A
1 Year-64%
1 Month+24%
Nexalin Technology last closing stock price
MetricPriceDate
Last closeUSD 0.462026-07-22
Nexalin Technology stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.6%USD 0.472026-07-15
1 month+24.03%USD 0.372026-06-22
3 month+7.05%USD 0.432026-04-23
Year to date-17.29%USD 0.562025-12-31
1 year-63.66%USD 1.272025-07-22
3 year-40.85%USD 0.782023-07-21
Since inception-78.62%USD 2.252022-09-16

Nexalin Technology Financials at a Glance

Market Cap

$10.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$275.58K

Net Income (TTM)

-$8.33M

EPS (TTM)

-$0.46

P/E Ratio

-1.00

Dividend

$0.00

Beta (Volatility)

1.30 (Average)

Price

$0.48

Volume

1,360

Open

$0.46

Previous Close

$0.48

Daily Range

$0.46 - $0.48

52-Week Range

$0.31 - $2.00

Estimated Earnings Date

Sep 2, 2026

NXL News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Nexalin Technology

Nexalin makes medical devices that help treat anxiety and insomnia without drugs. Its products use gentle electrical stimulation to support mental health. People use these devices in clinics or at home to manage symptoms.

Products and Services

  • Gen-1 Device: Non-invasive device for anxiety, insomnia, and depression (U.S. sales paused); 45% of FY 2025 revenue.
  • Gen-2 SYNC: Clinical device for anxiety, insomnia, depression, and Alzheimer’s; in trials and regulatory review.
  • Gen-3 HALO: Home-use headset for remote mental health care; targets similar conditions as Gen-2.
  • Consumables: Single-use electrodes and cables; 30% of FY 2025 revenue.
  • Licensing Fees: Monthly device licensing; 16% of FY 2025 revenue.

Growth and Expansion

  • Entered China through a joint venture with Wider Come Limited in 2023.
  • Received regulatory approvals for Gen-2 device in China, Brazil, and Oman by 2025.
  • Formed Military & Government Advisory Board in 2025 for U.S. federal opportunities.
  • Began regulatory preparation and planning for expanded clinical trials of Gen-2 and Gen-3 devices in the U.S. during 2025.

What Makes Nexalin Stand Out

Nexalin’s patented technology delivers non-invasive, drug-free mental health treatment. Its recurring revenue model relies on single-use consumables. The company’s virtual clinic platform supports remote care and telehealth integration.

Five Things You Need to Know

  • Revenue was $301,647 in FY 2025, up 79% from FY 2024.
  • International sales made up 63% of FY 2025 revenue.
  • Gross margin reached 80% in FY 2025, up from 78% in FY 2024.
  • Net loss was $(8.2) million in FY 2025, 8% higher than FY 2024.

Bottom Line

Nexalin has shifted from U.S. device sales to global partnerships and digital health. The company’s focus is on innovation in non-invasive mental health solutions and recurring revenue streams.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

8

CEO

Mark White

Website

www.nexalin.com

Headquarters

Houston, TX 77056, US

NXL Financials

Key Financial Metrics (TTM)

Gross Margin

-102.86%

Operating Margin

-3084.22%

Net Income Margin

-3022.94%

Return on Equity

-191.88%

Return on Capital

-223.88%

Return on Assets

-225.48%

Earnings Yield

-100.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$10.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

22.01M

Volume

1.36K

Avg. Volume

605.17K

Financials (TTM)

Gross Profit

-$283.45K

Operating Income

-$8.50M

EBITDA

-$8.30M

Operating Cash Flow

-$5.24M

Capital Expenditure

-$82.92K

Free Cash Flow

-$5.33M

Cash & ST Invst.

$2.71M

Total Debt

$0.00

Nexalin Technology Performance Analysis

Nexalin Technology annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 1,321,357817.2%
20232023-12-31USD 110,748-91.6%
20242024-12-31USD 168,72152.3%
20252025-12-31USD 301,64778.8%
Nexalin Technology sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3072.1%
Q32025-09-30-74.3%
Q42025-12-31847.1%
Q12026-03-31-91.3%
Nexalin Technology annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.23-72.1%
20232023-12-31USD -0.63168.3%
20242024-12-31USD -0.8332.0%
20252025-12-31USD -0.50-39.2%
Nexalin Technology sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3033.3%
Q32025-09-30-30.0%
Q42025-12-31N/A
Q12026-03-3115.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$14.95K

-63.5%

Gross Profit

-$496.27K

-1907.4%

Gross Margin

-33.20%

N/A

Market Cap

$10.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.27M

N/A

Employees

8

N/A

Net Income

-$2.10M

-5.5%

EBITDA

-$2.09M

-5.2%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$2.71M

+32.1%

Total Debt

$0.00

N/A

Accounts Receivable

$43.00K

+197.0%

Inventory

$179.49K

+2.4%

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-2.25%

N/A

Return on Invested Capital

-2.94%

N/A

Free Cash Flow

-$1.76M

-23.6%

Operating Cash Flow

-$1.71M

-20.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
XCURExicure, Inc.
$1.76-8.81%
MODDModular Medical, Inc.
$2.96+6.09%
CLGNCollPlant Biotechnologies Ltd.
$0.32+0.00%
SCYXSCYNEXIS, Inc.
$3.96-2.35%

Trending Stocks

Symbol / CompanyPricePrice Chg
SMCISuper Micro Computer
$30.58+0.20%
NVDANvidia
$212.25+0.02%
NOKNokia
$10.28-0.03%
INTCIntel
$102.85-0.02%

Questions About NXL

What is the current price of Nexalin Technology?

Nexalin Technology is trading at $0.48 per share.

What is the 52-week range for Nexalin Technology?

Over the past 52 weeks, Nexalin Technology has traded between $0.31 and $2.00.

How much debt does Nexalin Technology have?

As of the most recent reporting period, Nexalin Technology reported total debt of $0.00.

How much cash does Nexalin Technology have on hand?

Nexalin Technology reported $1.21M in cash and cash equivalents in its most recent financial results.

What is Nexalin Technology’s dividend yield?

Nexalin Technology does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services